SGF29 is a chr16 reader component of SAGA-type histone acetyltransferase complexes (TFTC-HAT, ATAC, STAGA) 123. It functions through tandem Tudor domains that specifically recognize and bind trimethylated histone H3 lysine 4 (H3K4me3), with preference over dimethylated forms 34. SGF29 recruitment of SAGA complexes to H3K4me3-marked chr16 is essential for histone H3 acetylation and transcriptional activation 3. The protein participates in ER stress responses by promoting H3K4me3-dependent histone acetylation and cell survival 5. SGF29 forms phase-separated nuclear condensates during cellular senescence that facilitate recruitment of transcriptional factors to senescence-associated genes like CDKN1A 6. In disease contexts, SGF29 elevation drives c-Myc overexpression in hepatocellular carcinoma 7 and represents a non-oncogenic dependency in acute myeloid leukemia (AML) by regulating stem cell-associated genes like MEIS1 8. SGF29's Tudor domain is a therapeutic target in leukemia, with selective inhibitors demonstrating preclinical efficacy 9. Additionally, SGF29 promotes alternative lengthening of telomeres (ALT) in cancer cells 10.